Lost password ?
<< Back to Equity Research
Mouwasat Medical
MOUWASAT, THAT WORTHY SHOT
Sep 21 - In our last paper on Mouwasat (Sell, KSA) (as of 24/04/2020), we were right to advise investors to jump in the stock. They would have gained 71.2%. This impressive rally was fundamentally boosted by ...
Executive summary
Conflict of Interest
Pages 37
Language English
Publish on September 21, 2020
€ 500
VAT Exl.
You might be also interested by these reports :
Apr 08 AM
Mouwasat Medical
Target pushed up by strong results
Mar 26 AM
Dallah Healthcare
Target boosted by a strong outlook
Mar 26 AM
Mouwasat Medical
Mouwasat Medical increases its net profit by 10%
Mar 15 AM
Dallah Healthcare
A slightly-weaker-than-expected Q4
FIND A REPORT
CONCEPT
Each company is researched in depth using a structured robust and transparent process.

AlphaMena provides analyses based upon exhaustive and homogeneous information which allows to compare stocks geographically, sector-wise, and by thematic.

The analyses include actuarial as well as off balance-sheet data.
BloombergStarmineFactsetReutersCapital IQ